The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor
- PMID: 20180789
- DOI: 10.1111/j.1365-2036.2010.04272.x
The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor
Abstract
Background: Dexlansoprazole MR is a Dual Delayed Release proton pump inhibitor formulated to extend the duration of acid suppression.
Aim: To evaluate the pharmacokinetics and pharmacodynamics of dexlansoprazole MR dosed before 4 different meal times.
Methods: In this randomized, open-label, four-way crossover study, 48 healthy subjects received dexlansoprazole MR 60 mg once daily 30 min before breakfast, lunch, dinner or an evening snack. Pharmacokinetics of dexlansoprazole MR and intragastric pH were assessed over a 24-h postdose interval on day 5 for each regimen.
Results: Absorption was delayed when dexlansoprazole MR was administered before each regimen relative to breakfast; however, systemic exposures of dexlansoprazole at all regimens were bioequivalent. There were no statistically significant differences in mean 24-h intragastric pH between dosing before dinner or an evening snack vs. breakfast; however, there was a small (0.2), but statistically significant difference between lunch and breakfast. There was a statistically significant difference of 7 percentage points in the percentage of time intragastric pH was >4 for the snack regimen relative to the breakfast regimen, but there were no statistically significant differences between lunch or dinner compared with breakfast.
Conclusion: Dexlansoprazole MR provides comparable acid control when administered at different times of the day.
Similar articles
-
Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.Aliment Pharmacol Ther. 2009 Apr 15;29(8):824-33. doi: 10.1111/j.1365-2036.2009.03979.x. Epub 2008 Jan 20. Aliment Pharmacol Ther. 2009. PMID: 19243357 Clinical Trial.
-
Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.Aliment Pharmacol Ther. 2009 May 1;29(9):928-37. doi: 10.1111/j.1365-2036.2009.03984.x. Epub 2009 Feb 26. Aliment Pharmacol Ther. 2009. PMID: 19298580 Review.
-
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.Aliment Pharmacol Ther. 2009 Nov 15;30(10):1010-21. doi: 10.1111/j.1365-2036.2009.04137.x. Epub 2009 Sep 4. Aliment Pharmacol Ther. 2009. PMID: 19735233
-
Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.J Clin Pharmacol. 2009 Apr;49(4):444-54. doi: 10.1177/0091270008330155. J Clin Pharmacol. 2009. PMID: 19318694 Clinical Trial.
-
Dexlansoprazole MR for the management of gastroesophageal reflux disease.Expert Rev Gastroenterol Hepatol. 2011 Aug;5(4):439-45. doi: 10.1586/egh.11.37. Expert Rev Gastroenterol Hepatol. 2011. PMID: 21780890 Review.
Cited by
-
Effect of Food and Dosing Regimen on Safety and Efficacy of Proton Pump Inhibitors Therapy-A Literature Review.Int J Environ Res Public Health. 2021 Mar 29;18(7):3527. doi: 10.3390/ijerph18073527. Int J Environ Res Public Health. 2021. PMID: 33805341 Free PMC article. Review.
-
Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.Clin Gastroenterol Hepatol. 2018 Jun;16(6):800-808.e7. doi: 10.1016/j.cgh.2017.09.033. Epub 2017 Sep 28. Clin Gastroenterol Hepatol. 2018. PMID: 28964908 Free PMC article.
-
Proton pump inhibitors for the treatment of patients with erosive esophagitis and gastroesophageal reflux disease: current evidence and safety of dexlansoprazole.Clin Exp Gastroenterol. 2016 Jul 13;9:163-72. doi: 10.2147/CEG.S91602. eCollection 2016. Clin Exp Gastroenterol. 2016. PMID: 27471402 Free PMC article. Review.
-
The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.Prz Gastroenterol. 2017;12(4):244-249. doi: 10.5114/pg.2017.72097. Epub 2017 Dec 14. Prz Gastroenterol. 2017. PMID: 29358992 Free PMC article. Review.
-
The Medical Management of Gastro-Oesophageal Reflux Disease.Inflamm Intest Dis. 2016 Jul;1(2):96-99. doi: 10.1159/000446589. Epub 2016 Jun 3. Inflamm Intest Dis. 2016. PMID: 29922663 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources